Rocklatan is a prescription combination eye drop pairing netarsudil and latanoprost to lower intraocular pressure in adults with open-angle glaucoma or ocular hypertension. FDA approved it in March 2019 after two successful phase 3 trials confirmed superior IOP reduction over monotherapy.
Rocklatan targets two drainage pathways at once, producing IOP reductions that exceed either ingredient used alone. Over 60% of trial patients achieved 30% or greater pressure reduction, nearly twice the rate seen with latanoprost alone. Side effects like eye redness affect most users but rate as mild to moderate in 90% of cases. Cost without insurance runs $300 to $500 per month.
This review covers how Rocklatan works, what real users report, how it compares to Rhopressa and Vyzulta, and whether the high monthly cost is justified for glaucoma patients. The goal is to help patients and caregivers make an informed treatment decision based on clinical evidence and real-world feedback.
What Are Rocklatan Eye Drops?
Rocklatan is a brand-name prescription eye drop combining netarsudil and latanoprost to reduce intraocular pressure in adults with open-angle glaucoma or ocular hypertension. In fact, it targets two separate drainage pathways at once. Patients use it once daily in the evening under ophthalmologist supervision.
FDA approved the drug in March 2019, following development by Aerie Pharmaceuticals. Alcon now manufactures Rocklatan. Ophthalmologists and optometrists prescribe it for documented cases of elevated eye pressure requiring pharmacological control.
Here’s the thing: Rocklatan goes in as one drop per eye each evening. Patients using other eye drops must wait at least 5 minutes between applications. The separation prevents one drop from washing out the other before absorption happens.
Drug Facts:
| Feature | Details |
| Brand Name | Rocklatan |
| Drug Class | ROCK inhibitor / Prostaglandin analog |
| Approval Date | March 2019 (FDA) |
| Availability | Prescription only |
| Generic Available | No |
What Are the Active Ingredients in Rocklatan?
Netarsudil 0.02% is a Rho kinase (ROCK) inhibitor and the active ingredient originally found in Rhopressa, a first-in-class medication specifically designed to target the diseased trabecular meshwork. To be clear, the trabecular meshwork is the eye’s primary drainage structure and the main site of disease in open-angle glaucoma.
Latanoprost 0.005% is a prostaglandin analog, the most widely prescribed class of glaucoma eye drops. Latanoprost increases fluid outflow through the uveoscleral route. That’s a secondary drainage pathway completely independent of the trabecular meshwork.
Rocklatan comes as an ophthalmic solution in a multi-use dropper bottle. One strength only exists: 0.02% netarsudil and 0.005% latanoprost. The fixed-dose combination simplifies the regimen compared to juggling two separate bottles.
What Is Rocklatan Used For?
Rocklatan is FDA-approved to reduce elevated intraocular pressure (IOP) in adults with open-angle glaucoma or ocular hypertension, two of the most common causes of vision loss in adults. Controlling IOP is the primary treatment goal in both conditions.
Open-angle glaucoma occurs when the eye can’t drain fluid properly through the trabecular meshwork. The resulting pressure buildup damages the optic nerve over time. Left untreated, open-angle glaucoma progressively destroys peripheral vision first, then central vision.
Ocular hypertension means eye pressure is above normal due to fluid accumulation. The condition raises glaucoma risk significantly. Not everyone with ocular hypertension develops glaucoma, but those with high IOP benefit from pressure-lowering treatment like Rocklatan.
How Do Rocklatan Eye Drops Work?
Rocklatan reduces intraocular pressure through two complementary pathways: netarsudil restores outflow through the diseased trabecular meshwork while latanoprost increases drainage through the uveoscleral route. Bottom line: the dual-mechanism approach lowers IOP more than either drug achieves on its own.
Netarsudil inhibits Rho kinase, an enzyme that increases resistance in the trabecular meshwork. Think of it this way: the trabecular meshwork is like a clogged drain, and netarsudil clears the blockage. Reducing resistance there restores the eye’s natural outflow capacity.
Latanoprost acts through a completely different route, the uveoscleral pathway. The prostaglandin analog opens secondary drainage channels so aqueous humor exits through the ciliary body rather than the meshwork. Both pathways working at the same time produce additive IOP reduction.
Rocklatan Mechanism of Action:
| Ingredient | Class | Pathway |
| Netarsudil 0.02% | ROCK inhibitor | Trabecular meshwork (conventional) |
| Latanoprost 0.005% | Prostaglandin analog | Uveoscleral route (unconventional) |
How Long Does Rocklatan Take to Work?
Rocklatan begins lowering intraocular pressure within a few hours of the first dose, with measurable and consistent pressure reduction typically observed within 1-2 weeks of regular evening use. Patients shouldn’t expect immediate dramatic results on day one.
Here’s what most people miss: Rocklatan is a long-term medication. Stopping use causes IOP to return to pre-treatment levels within days. Ophthalmologists prescribe it for indefinite use because open-angle glaucoma and ocular hypertension are chronic conditions requiring sustained pressure control.
What Are the Benefits of Rocklatan?
Rocklatan offers superior intraocular pressure lowering compared to either ingredient alone by simultaneously targeting two separate aqueous humor drainage pathways, producing additive pressure reduction proven in phase 3 trials. The combination delivers what monotherapy simply can’t match.
The once-daily evening dosing schedule is a significant practical benefit. Patients need only one drop per eye each evening rather than managing two separate bottles with different timing schedules. Simplified regimens improve adherence, which directly impacts glaucoma outcomes over time.
In MERCURY 1 and MERCURY 2 phase 3 trials, over 60% of Rocklatan patients achieved 30% or greater IOP reduction. The good news? That rate was nearly twice what patients on latanoprost alone achieved. This consistent clinical superiority positions Rocklatan as the obvious step-up option when prostaglandin monotherapy isn’t enough.
Key Benefits:
- Dual-pathway IOP reduction exceeding either monotherapy component.
- Once-daily evening dosing simplifies the glaucoma treatment regimen.
- Over 60% of trial patients achieved 30% or greater IOP reduction.
- Nearly twice as many patients reached target pressure vs latanoprost alone.
- FDA-approved with 12-month safety and efficacy data from two phase 3 trials.
Is Rocklatan More Effective Than Latanoprost Alone?
Yes. Rocklatan achieved statistically superior IOP reduction over latanoprost at every measured time point during the 90-day primary efficacy period and through 12 months in the MERCURY 1 and MERCURY 2 phase 3 trials. The advantage was consistent and significant across all time points.
Target pressure achievement data makes the case even stronger. Nearly twice as many Rocklatan patients reached 16 mmHg (millimeters of mercury) or lower compared to latanoprost. Nearly three times as many reached 14 mmHg or lower, a threshold strongly associated with slowing glaucoma progression.
Does Rocklatan Lower Eye Pressure Significantly?
Yes. Rocklatan delivers clinically meaningful intraocular pressure reductions exceeding 30% in the majority of treated patients, surpassing the reduction achieved by latanoprost or netarsudil used as individual monotherapies. The clinical evidence base is robust.
In the MERCURY studies, more than 60% of Rocklatan patients hit 30% or greater IOP reduction. By comparison, approximately 33% of latanoprost patients in the same trials reached that threshold. The gap illustrates exactly how the dual-pathway mechanism translates into real clinical advantage.
What Do Rocklatan Reviews Say?
Rocklatan has an average rating of 3.4 out of 5 from 6 reviews on WebMD, with approximately 67% of reviewers reporting a positive effect from the medication for their glaucoma or ocular hypertension. The limited review count reflects the drug’s specialized glaucoma indication.
Reviews consistently highlight effective IOP control as the primary positive outcome. The once-daily dosing schedule gets praise for convenience compared to multi-drop regimens. Patients who switched from using separate latanoprost and netarsudil bottles appreciate the simplified single-bottle approach.
Negative sentiment in reviews focuses on two main areas: cosmetic side effects and cost. Persistent eye redness is the most frequently mentioned complaint. High out-of-pocket expense without insurance or copay assistance is a recurring concern among cost-sensitive patients.
What Positive Experiences Do Rocklatan Users Report?
Satisfied Rocklatan users report successful IOP lowering to target pressure ranges, reduced need for multiple medications, and appreciation for the convenience of a single once-daily combination drop replacing two separate prescriptions. Efficacy is the dominant positive theme.
And here’s what clinches it for many users: their ophthalmologists confirm lower IOP measurements at follow-up visits. Objective pressure data reinforces the subjective sense that Rocklatan is working. Patients who had struggled to reach target pressure on latanoprost alone often see meaningful improvement after switching.
What Are Common Complaints About Rocklatan?
The most frequent Rocklatan complaints are persistent eye redness from conjunctival hyperemia, stinging or burning on instillation, and high out-of-pocket cost for patients without adequate insurance coverage or copay assistance programs. These three issues dominate negative reviews.
Iris color changes from the latanoprost component concern users with light-colored eyes. Latanoprost increases melanin in the iris, potentially causing permanent darkening. Users with blue or green eyes worry about irreversible pigmentation that affects appearance, especially when only one eye receives treatment.
Persistent red eyes affect quality of life for some patients. Visible conjunctival hyperemia draws attention and is sometimes mistaken for infection or allergy. Some users discontinue despite adequate IOP control because the cosmetic impact becomes socially unacceptable to them.
Common Complaints:
- Persistent eye redness (conjunctival hyperemia) affecting appearance.
- Stinging or burning sensation on instillation.
- High out-of-pocket cost without insurance coverage.
- Irreversible iris darkening in light-eyed patients.
- Eyelash and eyelid pigmentation changes.
Rocklatan vs. Rhopressa: Which Is Better?
Rocklatan contains Rhopressa (netarsudil 0.02%) plus latanoprost 0.005%, making it an expanded version of Rhopressa with a second active ingredient for superior IOP lowering through an additional drainage pathway. In fact, Rocklatan isn’t competing with Rhopressa; it builds directly on it.
Efficacy data favors Rocklatan over Rhopressa for patients who can tolerate both drug classes. MERCURY trial data showed Rocklatan surpassed both latanoprost and netarsudil monotherapies at all measured time points. Is Rhopressa ever the better pick? Yes, for patients who can’t tolerate prostaglandins.
Patient selection determines which drug is appropriate. Rhopressa suits patients with contraindications to prostaglandin analogs, such as a history of macular edema or inflammatory eye disease. Rocklatan is preferred when maximal IOP lowering is needed and both drug classes are well tolerated.
Rocklatan vs. Rhopressa Comparison:
| Feature | Rocklatan | Rhopressa |
| Active Ingredients | Netarsudil + Latanoprost | Netarsudil only |
| Pathways Targeted | Two (trabecular + uveoscleral) | One (trabecular meshwork) |
| IOP Reduction | Superior in MERCURY trials | Effective as monotherapy |
| Best For | Patients tolerating both classes | Prostaglandin-intolerant patients |
Rocklatan vs. Vyzulta: How Do They Compare?
Rocklatan combines a ROCK inhibitor (netarsudil) with a traditional prostaglandin (latanoprost), while Vyzulta (latanoprostene bunod) is a single nitric oxide-donating prostaglandin analog that releases both a prostaglandin and nitric oxide upon metabolism. The two drugs take different secondary approaches to the same goal.
No direct head-to-head trial compares Rocklatan against Vyzulta. Both demonstrate superior IOP lowering compared to latanoprost monotherapy, but through different pathways. Ophthalmologists choose between them based on patient factors, side effect profiles, and insurance formulary placement.
What Are the Side Effects of Rocklatan?
The most common side effect of Rocklatan is conjunctival hyperemia (redness of the eye), which was reported in the majority of clinical trial participants, with 90% of cases rated as mild to moderate in severity by trial investigators. For most patients, the redness is manageable.
Other frequently reported side effects include instillation site pain, corneal verticillata (whorled deposits in the corneal epithelium visible only under slit-lamp), and conjunctival hemorrhage (small visible amounts of bleeding on the white of the eye). These events are generally mild and reversible.
Here’s the reassuring part: only 5% of patients in the MERCURY trials discontinued Rocklatan due to conjunctival hyperemia. The 95% continuation rate reflects acceptable tolerability for a glaucoma medication with a dual active ingredient profile.
Common Side Effects:
- Conjunctival hyperemia (eye redness) — reported in most trial participants.
- Instillation site pain or discomfort.
- Corneal verticillata (visible deposits under slit-lamp only).
- Conjunctival hemorrhage (minor eye bleeding).
What Are the Serious Side Effects of Rocklatan?
Serious Rocklatan side effects include macular edema (fluid accumulation affecting central vision), permanent iris pigmentation darkening, eyelash and eyelid color changes from latanoprost, and bacterial keratitis from improper dropper technique or contaminated bottles. These are rare, but they matter.
Latanoprost causes eyelash hypertrichosis (increased growth), eyelash darkening, and darkening of eyelid skin in the periocular area. Changes may be asymmetric if only one eye receives treatment. Some of these cosmetic changes are permanent even after stopping the medication.
Allergic reactions require immediate medical attention. Signs include significant eye swelling, severe eye pain, or difficulty breathing. Hypersensitivity reactions are uncommon but patients should stop Rocklatan and contact their ophthalmologist right away if these symptoms appear.
Can You Use Rocklatan While Wearing Contacts?
No. Contact lenses must be removed before instilling Rocklatan, and lenses can be reinserted 15 minutes after the drop is applied; this waiting period prevents the benzalkonium chloride preservative from absorbing into soft contact lens material. Skipping lens removal risks lens damage and eye irritation.
Most practitioners recommend instilling Rocklatan in the evening after lenses have been removed for the night, eliminating any need to time reinsertion. This approach maximizes convenience and ensures proper medication absorption without lens interference.
Is Rocklatan Safe During Pregnancy?
No. Rocklatan is not recommended during pregnancy because latanoprost has shown potential to cause fetal harm in animal studies, and the risk to human fetuses can’t be excluded based on available safety data. Pregnancy considerations are serious here.
The safety of Rocklatan during breastfeeding is unknown. It’s not established whether netarsudil or latanoprost passes into breast milk in meaningful amounts. Physicians generally recommend caution and discuss alternative glaucoma treatments for breastfeeding patients.
Women of childbearing age using Rocklatan should discuss contraception and pregnancy planning with their ophthalmologist before conception. Alternative glaucoma treatments with better-characterized safety profiles during pregnancy do exist. Timely medication transitions protect both maternal glaucoma control and fetal safety.
How Much Does Rocklatan Cost?
Without insurance, Rocklatan typically costs between $300 and $500 per month at retail pharmacies in the United States ($3,600 to $6,000 annually), with exact prices varying by pharmacy, location, and quantity dispensed. The high cost reflects its brand-only status.
The good news? Alcon offers the MyAlcon Together patient support program, which provides savings cards and copay assistance to eligible commercially insured patients. Patients can enroll through their doctor’s office or directly through the Alcon website. The program helps reduce out-of-pocket costs for qualifying participants.
Most commercial insurance plans and Medicare Part D plans include Rocklatan on their formularies. Prior authorization is frequently required before coverage is approved. Copay amounts after insurance vary widely, from near zero with a manufacturer coupon to $50-$100 per month for some plan designs.
Cost Overview:
| Scenario | Estimated Monthly Cost |
| Without insurance (retail) | $300 – $500 |
| With commercial insurance | Varies by plan; often $30 – $100 |
| With Alcon copay card (eligible patients) | May be significantly reduced |
| Medicare Part D | Varies by plan; prior auth often required |
Is There a Generic for Rocklatan?
No. No generic version of Rocklatan is currently available; the combination product remains brand-only, which directly contributes to the high out-of-pocket cost for patients without insurance or inadequate coverage for branded glaucoma medications. Generic availability remains uncertain.
Generic latanoprost is widely available at very low cost from major pharmacy chains. Patients who can’t afford Rocklatan may discuss using generic latanoprost plus a separately prescribed generic ROCK inhibitor with their doctor. The trade-off is two separate bottles with different application timing requirements.
Where Can You Buy Rocklatan?
Rocklatan is available at major pharmacy chains throughout the United States, including CVS, Walgreens, Rite Aid, and Walmart Pharmacy, with a valid prescription from a licensed ophthalmologist or optometrist. Major retail pharmacies stock it consistently.
Rocklatan is a prescription-only medication; it can’t be purchased without a valid script. Online pharmacy services require prescription verification before dispensing. Patients should verify that any online pharmacy is licensed and accredited before ordering specialty medications like Rocklatan.
Eligible patients can enroll in the MyAlcon Together program through their prescriber’s office or at the Alcon website. The enrollment process is straightforward and provides savings card access after eligibility verification. The program is designed for commercially insured patients and doesn’t apply to government insurance programs.
Is Rocklatan Worth It?
Yes. Rocklatan is clinically proven to lower intraocular pressure more than latanoprost alone in patients with open-angle glaucoma or ocular hypertension, making it a strong and well-evidenced step-up option when prostaglandin monotherapy fails to reach target pressures. The evidence base is solid.
Patients already on latanoprost who need further IOP lowering are ideal Rocklatan candidates. Those with insurance coverage or access to the Alcon copay program benefit most from the drug’s dual-pathway efficacy in a convenient once-daily regimen. The clinical trial data supports choosing Rocklatan over adding a second separate medication.
Patients sensitive to cosmetic eye changes, those who are pregnant, or patients without adequate insurance should consider alternative approaches with their ophthalmologist. Rocklatan delivers real clinical value for the right patient. Matching the medication to the patient’s profile and financial situation determines whether it’s the best choice.
Is Rocklatan Worth the Price?
Yes. For patients needing additional IOP lowering beyond latanoprost alone, Rocklatan delivers clinically proven superior efficacy in a convenient once-daily formulation; the cost is well justified for patients whose insurance covers most of the expense. Value depends heavily on coverage.
High out-of-pocket costs create a significant barrier for uninsured and underinsured patients. Patients with commercial insurance paying minimal copays report strong satisfaction with Rocklatan’s effectiveness relative to their cost. The cost-benefit calculation shifts dramatically based on individual insurance status and access to manufacturer savings programs.